Mozart Therapeutics, Inc.’s Post

Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers for Advanced Chronic Kidney Disease: A Systematic Review and Retrospective Individual Participant–Level Meta-analysis of Clinical Trials https://lnkd.in/dGMgqgMm

💻 Virtual webinar! Join Jennifer B Green, MD, and David Charytan, MD, MSc for a comprehensive review of the renal benefits associated with GLP-1 receptor agonists! Participants will explore the latest clinical data, proposed mechanisms, and evidence-based guidelines to optimize glycemic control and improve cardiorenal outcomes in patients with type 2 diabetes and chronic kidney disease. Don’t miss it: https://bit.ly/3BSdJ7S

Metabolic dysfunction-associated steatotic liver disease (MASLD) is an epidemic that has already reached us and requires close monitoring. In the long term it is associated ☠ With two- to three-fold increase in the risk of death from liver problems and hepatocellular carcinoma. 👯 At least 6 to 7 people out of every 10 people with type 2 diabetes may have this condition. Research and appropriate public policies will allow its control. https://lnkd.in/g-hhPgv5

Comings and Goings: Researchers detail data from First 15 autoimmune disease patients treated with CAR-T (NEJM) In these case studies 15 patients with systemic lupus erythematosus (8 patients), idiopathic inflammatory myositis (3 patients), or systemic sclerosis (4 patients) who received a single infusion of CD19 chimeric antigen receptor (CAR) T cells after preconditioning with fludarabine and cyclophosphamide were followed for up to 2 years (12-15 mo median). Overall, CD19 CAR T-cell transfer appeared to be feasible, safe, and efficacious across three different autoimmune diseases, potentially providing rationale/promise for further controlled clinical trials. see Article: https://lnkd.in/ebjFcEex https://lnkd.in/eVmXe2Wx

𝗡𝗼𝘃𝗼 𝗡𝗼𝗿𝗱𝗶𝘀𝗸'𝘀 𝗢𝗿𝗮𝗹 𝗦𝗲𝗺𝗮𝗴𝗹𝘂𝘁𝗶𝗱𝗲: 𝗔 𝗕𝗿𝗲𝗮𝗸𝘁𝗵𝗿𝗼𝘂𝗴𝗵 𝗳𝗼𝗿 𝗧𝘆𝗽𝗲 𝟮 𝗗𝗶𝗮𝗯𝗲𝘁𝗲𝘀 Novo Nordisk today announced the headline results from the SOUL cardiovascular outcomes trial. The double-blinded, randomised trial compared oral semaglutide to placebo as an adjunct to standard of care for the prevention of major adverse cardiovascular events (MACE). The trial enrolled 9,650 people with type 2 diabetes and established cardiovascular disease (CVD) and/or chronic kidney disease (CKD). As part of standard of care, 49% of patients received SGLT2i at some point during the trial. 🔗 https://lnkd.in/gu2UWyCn #type2diabetes #cardiovascular #oralsemaglutide #clinicaltrialresults

Evaluation of glucagon-like peptide-1 receptor agonists (#GLP1-RA) in systemic #lupus erythematosus patients (SLE), data from the NYU Lupus Cohort 🔹GLP1-RAs were rarely used in SLE patients ―of 1211 patients in the cohort, only 24 had received a GLP1-RA― and were not associated with increased disease flares. 🔹GLP1-RAs were associated with a significant reduction in BMI after 1-4 months and 6-10 months of use. 🔹GLP1-RAs may be useful adjunctive agents for cardiovascular risk modification in SLE patients. 🔗https://lnkd.in/d79TY_Uy

α1−ANTITRYPSIN DEFICIENCY is an Autosomal recessive disease→↓Hepatocyte α1−antitrypsin, being an enzyme which normally protects organs (esp. the Lungs & Liver) from inflammatory proteolytic digestion (esp. Leukocyte Elastases & Proteases) Plasma levels <10% of normal→relatively ↑proteolytic activity→PREMATURE EMPHYSEMA (age <50 years), esp. if the patient smokes It is estimated that only 10% of patients w/ α1−antitrypsin deficiency are diagnosed Consider the diagnosis in: •Non−smokers •Young patients (age <50 years) •Those w/ concomitant Liver disease knowmedicine.net

Did you know spinal and bulbar muscular atrophy (SBMA), also known as Kennedy’s Disease, is a rare X-linked PolyQ disease estimated to affect approximately 4,000 to 24,000 men in the U.S. There are currently no U.S. FDA approved treatments available for this devastating neurodegenerative disease. This #RareDiseaseDay, learn more about SBMA and Avenue’s ongoing Phase 1b/2a trial of AJ201 here: https://lnkd.in/e8ikA3rc #SBMA #KennedysDisease